A green fluorescent protein (gfp) gene was ligated to the Lactobacillus reuterispecific nisin-inducible expression-secretion vector pNIES, generating a pNIES-GFP vector capable of secreting the cloned gene as a GFP-fusion protein with fluorescent activity. To develop this system as a live vehicle carrying the heat-stable enterotoxin (ST) and heat-labile enterotoxin B (LT B ) of the enterotoxigenic Escherichia coli (ETEC), a recombinant 5 0 -ST-LT B -3 0 DNA fragment was cloned into pNIES-GFP. The resulting L. reuteri/pNIES-GFP:STLT B system was found to possess the capability of adhering to the mice gut, secreting GFP:STLT B product at 0.14 and 0.026 pgcell À1 under induced and noninduced conditions, respectively. Further analysis of the GFP:STLT B product confirmed its gangliosidebinding ability, LT B antigenicity and relative freedom from the ST-associated toxicity, making it suitable for use as an oral vaccine in mice. Oral inoculation of the L. reuteri/pNIES-GFP:STLT B culture in mice elicited significant (P o 0.01) serum IgG and mucosal IgA antibodies against the STLT B antigen. These immunized mice were subsequently challenged with ETEC and showed full protection against the fluid influx response in the gut. This is the first report of using L. reuteri as a vaccine carrier to induce complete immunologic protection against ETEC.
Introduction
Lactobacillus reuteri, frequently found in the gastrointestinal tracts of humans and animals, has been discovered to have advantages that make it suitable for use as a probiotic (Chung et al., 1989; Seegers, 2002; Tubelius et al., 2005) . Further development of such a microbe with probiotic effects as a live vehicle carrying immunological molecules would provide the gastrointestinal tract with extra medical benefits. To implement this goal, L. reuteri, along with many other Lactobacillus species already applied in the probiotic field, has been intensively explored for its possible role as a vaccine carrier during the last decade.
However, to our knowledge, only four L. reuteri species -Lactobacillus acidophilus (Chu et al., 2005) , L. casei (Zegers et al., 1999; Shaw et al., 2000; Ho et al., 2005) , L. johnsonii (Scheppler et al., 2002) and L. plantarum (Shaw et al., 2000; Grangette et al., 2002; Reveneau et al., 2002; Corthesy et al., 2005) -have produced foreign antigens (i.e. urease B, proteinase B, tetanus toxin fragment C and Coronavirus glycoprotein S) and elicited a specific immune response in the mucosal membrane system. One reason for this small number may be the limited sources of expression-secretion vectors (ESV), which, because they are frequently speciesspecific, were difficult to adapt to other Lactobacillus reuteri species . Therefore, constructing a new ESV is nearly inevitable, as a Lactobacillus reuteri species of interest is chosen for live vehicle development. Given the considerable phylogenic distances existing among the more than 60 Lactobacillus reuteri species (Reveneau et al., 2002) , which usually vary greatly in efficacy of transcription, translation and secretion signals (Grangette et al., 2002; Scheppler et al., 2002; Seegers, 2002) , a broad host-spectrum ESV functional in many L. reuteri species seems unlikely to be developed in the near feature. Accordingly, an L. reuteri-specific nisin-inducible ESV, the pNIES, was constructed and found to possess advantages, including a high secretion efficiency, a high constitutive ES activity and also a satisfactory inducible capacity, appropriate for use in L. reuteri as a vaccine vector .
Enterotoxigenic Escherichia coli (ETEC) had been responsible for a sizable fraction of the morbidity and mortality burden from diarrheal diseases suffered by young children in developing countries (Guzman-Verduzco & Kupersztoch, 1987) . The virulence of ETEC is directly related to the production of heat-labile (LT) and/or heat-stable (ST) toxins, which alter the hydrosaline balance of the intestinal mucosa. To our knowledge, no licensed vaccine is available for ETEC thus far. Apparently, more efforts are still required before this important goal can be realized.
Fusion of ST and LT enterotoxin B (LT B ) together can successfully evoke high titers of neutralization antibodies efficiently against both ST and LT B (Clements, 1990) . In addition, a recombinant 5 0 -ST-LT B -3 0 DNA template from the pGSK51 (Guzman-Verduzco & Kupersztoch, 1987) is immediately available. Bearing these in mind, a STLT B gene encoding the 53-amino acid ST polypeptide (including the 19-amino acids of active ST enterotoxin) and 105-amino acid LT B polypeptide, devoid of their original leader peptides, was PCR-amplified and tested for its potential role as a subunit vaccine through our newly constructed L. reuteri/ pNIES system.
In this study, the pNIES is upgraded to a pNIES-GFP, which is able to express and secrete the cloned STLT B gene as a GFP:STLT B fusion protein with fluorescent activity. This L. reuteri/pNIES-GFP system and its secreted GFP:STLT B protein were characterized to evaluate their suitability for use in the gastrointestinal tract of mice. Further mice immunization, antibody titers (IgG and IgA) detection, and protection tests are also included in this report.
Materials and methods

Bacterial strains and growth conditions
The bacterial strains and recombinant plasmids used in this study are listed in Table 1 . All experiments were performed with strains L. reuteri DSM20016 (L. reuteri 20016) and WT3-3 (L. reuteri 3-3). Lactobacillus reuteri 20016 is the prototype that originated from human intestine (Kandler et al., 1980) , whereas L. reuteri 3-3 is an isolate from mice cecum.
All cloning steps were done with E. coli TG1 strain (New England Biolabs) grown in LB medium (Difco) at 37 1C under aeration. Lactobacillus reuteri strains were cultured in buffered MRS broth (Difco) containing 0.2 M potassium phosphate (pH 7) at 37 1C without shaking. When required, erythromycin was added to the culture medium at final concentrations of 10 and 150 mg mL À1 for recombinant L. reuteri (rL. reuteri) and E. coli strains, respectively.
Plasmid construction and DNA manipulation
Plasmids from E. coli were extracted using an alkaline lysis method and L. reuteri plasmids were isolated as described by Chassy & Giuffrida (1980) . Restriction endonucleases, T4 DNA ligase, and Taq polymerase were purchased from New England Biolabs and used according to the manufacturer's recommendations. Electroporations of L. reuteri and E. coli were performed as described by Lin & Chung (1999) .
The construction scheme for pNIES-GFP:STLT B is shown in Fig. 1 . The expression-secretion vector pNIES was constructed previously and the gfp gene (795 bp) was PCR-amplified from pQBI25-GFP (Qbiogene) using oligonucleotides 5 0 -TGACTAGTGCTAGCAAAGGA GA and 5 0 -GTCAGAATTCGCGAAGCTTGCT (the restriction sites are underlined) as primers. The PCR product of gfp gene, after treatment with SpeI/EcoRI, was ligated to the SpeI/EcoRI-digested pNIES, creating the plasmid pNIES-GFP ( Fig. 1a ). Subsequently, an STLT B gene (510 bp), produced by PCR-amplification from the pGSK51 (Guzman-Verduzco & Kupersztoch, 1987) using primer sets of ST-F (5-GCAGGATCC ATATGAAAAAATCA-3 0 ) and LT B -R (5 0 -CTAGAATTCTTTTAAG AAAC-3 0 ), was digested with BamHI/EcoRI and inserted into the corresponding sites in pNIES-GFP to generate the pNIES-GFP:STLT B (Fig. 1b ).
Standard PCR was carried out with an automated thermal cycler (PerkinElmer). Amplification was performed with 1 ng plasmid DNA under the following conditions: 2 min at 94 1C followed by 30 cycles consisting of 30 s at 94 1C, 30 s at 55 1C, and 45 s at 72 1C and a final step of 7 min at 72 1C. To produce large amounts of STLT B protein in E. coli, the BamHI/EcoRI STLT B fragment was cloned into the expression vector pET32c (Novagen) to create the pET-STLT B . The integrity of DNA sequencing in every step of the cloning process as mentioned above was confirmed by sequence analysis.
Epifluorescence microscopy
Fluorescent activity of the L. reuteri/pNIES-GFP:STLT B (recombinant L. reuteri, rL. reuteri) cells was directly ob-served by eye using an epifluorescence microscope (Olympus model BX60) fitted with an FITC filter set. Activation of the expression of GFP fusion protein was performed as described in .
Preparation of cell lysate and culture supernatant for protein analysis
Overnight rL. reuteri cultures were used to inoculate fresh MRS media at 1 : 50 dilution. After incubation for 1 h, the cultures were added (induced culture), or not (noninduced culture), with nisin A (Sigma) at a final concentration of 50 ng mL À1 and allowed to grow for a further 3 h before being adjusted with additional MRS broth to an OD at 600 nm of 0.25-0.27 (c. 1 Â 10 8 CFU mL À1 ). Then, 10 mL of the OD-adjusted culture was centrifuged and the supernatant concentrated to 1/100 volume with an Amicon PM-30 concentrator (Millipore), which was used latterly as the supernatant fraction in the protein analysis. The cell pellet was washed twice, resuspended in 100 mL lysis buffer (1 mL of 10 mMTris-HCl buffer containing 100 mg lysozyme and mutanolysin), and incubated at 37 1C for 3 h to produce the protoplast. Sonication of the protoplast was performed with an ultrasonic homogenizer (Labsonic 2000; Sartorius BBI Systems) from which the clear lysate was obtained by centrifugation and used as the intracellular fraction for protein analysis. 
Protein analysis
To visualize the proteins in the lysate and supernatant, the protein concentrations of the samples were analyzed using a Bio-Rad protein assay kit, mixed well with an equal amount of sample buffer (2 Â ), and then subjected to Western blot analysis (Martín et al., 2004) , in which polyclonal rabbit antiserum against GFP (Invitrogen) and alkaline phosphatase-conjugated goat anti-rabbit IgG antibody (Sigma) were used for the immunoblotting target protein detection. Quantification of the protein in gel was performed by comparing the signal scanned from the target protein with that from the purified GFP:STLT B (as a standard), using an Alphaimager image-analyzing system (Alpha Innotech) and the computer program ALPHAIMAGER TM 2200 version 5.5 as described in .
The ganglioside binding activity of the GFP:STLT B protein was examined following procedures described by Slos et al. (1998) . Briefly, microtiter plates, precoated per well with 200 ng of the mixed gangliosides (Sigma) in carbonatebicarbonate coating buffer (pH 9.6), were loaded with 100 mL of the concentrated supernatant sample, followed by the addition of rabbit anti-LT B antiserum (Immunology Consultants Laboratory) and p-nitrophenyl phosphate (Sigma). Absorbance was measured at 405 nm.
Toxicity assay
The suckling mouse assay, as descried by Giannella (1976) , with slight modifications, was performed to determine the ST toxicity of GFP:STLT B protein. In brief, solutions containing 0.1, 0.15 and 0.5 mg mL À1 of ST were prepared by dissolving and diluting the purified ST (100 000 U mg À1 , Sigma) with phosphate-buffered saline (PBS) (containing 1% bovine serum albumin and 0.2% Trypan blue dye). The same process was also performed in preparing the 10 and 100 mg mL À1 GFP:STLT B solutions from a concentrated rL. reuteri culture supernatant, of which the GFP:STLT B concentration was estimated in advance using an ALPHAIMAGER image-analyzing system as mentioned above. To assay the ST toxicity in mice, five groups of infant SPF BALB/c mice (3 days old, five mice per group), purchased from the National Laboratory Animal Center (NLAC, Taipei, Taiwan) and housed in cages with free access to water and feed as approved by the local veterinary office, were intragastrically inoculated by group with 100 mL of one of the aforementioned concentrations of ST or GFP: STLT B solutions per mouse. After 3 h, the animals were sacrificed and dissected. Data were collected only from those showing blue coloration in the stomach, which is evidence of a successful inoculation of the solution into the stomach. The entire intestine and remaining carcass were weighed separately, and the weight ratio between the gut and remaining carcass (G/C ratio) calculated.
Survival of recombinant strains in feces
Two groups of mice (five mice per group) were, respectively, administered orally with rL. reuteri 3-3, or rL. reuteri 20016, at a dose of 1 Â 10 9 CFU per mouse. Fresh feces from five mice in each group were collected 2 days before and every day after the administration for 5 days, and crushed together in sterile PBS to obtain a pooled sample of 100 mg mL À1 of fecal suspension from each group, from which a serial dilution was made. Persistence was estimated by triplicate plating 100 mL of each appropriate dilution onto the Lactobacillus reuteri-selective Rogosa agar (Merck) containing 10 mg mL À1 erythromycin and counting the visible colonies after 48 h of anaerobic incubation at 37 1C. Ten randomly selected colonies per plate were further picked and examined for the fluorescent activity (Flu 1 ) with an epifluorescence microscope as described above, from which the percentage of Flu 1 colonies was obtained and used as an index to adjust the fecal CFU value (CFU 100 mg À1 feces) calculated from the Em r colonies.
Immunization procedures
The SPF BALB/c mice (aged 8 weeks), five mice per group, were housed in the same cage for 7 days prior to the commencement of experiment. To prepare the rL. reuteri for mice immunization, large volumes of MRS media were inoculated with overnight cultures at a concentration of 1 : 50. Nisin A was added to the cultures after incubation for 1 h. The cultures were then incubated for another 2 h and harvested by centrifugation (at 8000 g for 10 min at 4 1C) to obtain pellets, which were immediately resuspended in an administration buffer (0.2 M sodium bicarbonate, 5% casein hydrolysate, 0.5% glucose) (Robinson et al., 1997) and adjusted by an OD 600 nm reading to reach a concentration of 5 Â 10 9 CFU mL À1 . Mice were intragastrically inoculated with the freshly prepared cell suspensions daily at a dose of 0.2 mL per mouse for 3 days. This was repeated three times (one prime and two boosts) with a 2-week interval between each repeat. Ten days after each administration, individual sera and fresh fecal pellets were collected and treated as described by Robinson et al. (1997) . These vaccination experiments were carried out on at least two separate occasions and the results demonstrated to be reproducible.
Antibody determinations
STLT B protein was extracted from the IPTG-induced E. coli BL21 (DE3) (Novagen) transformed with pET-STLT B , and purified by Ni-affinity chromatography (Novagen) as recommended by the manufacturer. The titers of the sera (IgG) and fecal (IgA) anti-STLT B antibodies were determined by enzyme-linked immunosorbant assay (ELISA) as described by Grangette et al. (2002) . Briefly, polystyrene microtiter plates (Nunc), coated overnight at 4 1C with 1 mg of the purified STLT B , were added to the twofold serially diluted serum or fecal samples. Bound antibodies were detected using alkaline phosphatase conjugated goat antimouse IgG or IgA (Sigma), followed by color development using p-nitrophenyl phosphate as substrate. Absorbance was measured at 405 nm. End-point titers were defined as the highest dilution that gave an absorbance three times higher than background.
Challenge procedures: patent mouse gut (PMG) assay
In vivo enterotoxin neutralization was determined using a PMG assay as described by Guidry et al. (1997) with modifications. Briefly, all immunized mice were given sterile water containing 5 mg streptomycin per milliliter ad libitum for 3 days, and then fasted for 24 h, followed by sterile water only for an additional 6 h prior to challenge. When challenged, mice were inoculated intragastrically with 0.5 mL NaHCO 3 10% solution alone or in conjunction with 3 Â 10 8 , 1.5 Â 10 9 , or 3 Â 10 9 CFU of live ETEC organisms. The mice remained in their cages without food but with water ad libitum for 3 h, and were then sacrificed by CO 2 inhalation. The entire intestine and carcass were weighed separately and a G/C ratio was calculated for each animal.
Statistical analysis
The results are expressed as the mean AE SE of the mean (SEM). Statistical significance was evaluated by Student's t-test. Statistical significance was considered to be P o 0.05 or 0.01.
Results
Construction of the pNIES-GFP vector
As shown in Fig. 1a , a promoterless gfp gene was cloned into the L. reuteri-specific expression-secretion vector pNIES, generating a chimerical plasmid pNIES-GFP with eight unique cloning sites immediately downstream of the gfp gene. Lactobacillus reuteri transformed with pNIES-GFP exhibited intracellular and extracellular green fluorescent activity ( Fig. 2a ), indicating the gfp gene was successfully cloned and regulated under the expression and secretion elements in pNIES.
To test the function of pNIES-GFP in expressing and secreting the cloned gene of interest as a GFP-fusion product, the STLT B gene was ligated into its BamHI/EcoRI sites to translationally (in-frame) fuse with the upstream gfp gene. The resulting 9.6-kb plasmid pNIES-GFP:STLT B (Fig. 1b) , which was shown to contain the gfp:STLT B DNA fragment by restriction and PCR-amplification analysis ( Supplementary Fig. S1 ), was transformed into L. reuteri 20016 and L. reuteri 3-3. The L. reuteri transforments carrying pNIES-GFP:STLT B were found to exhibit fluorescent activities (Flu 1 ) in their cytoplasm and culture supernatant, though with a yellow color (Fig. 2) . Further Western blot analysis of the culture supernatant detected the presence of a 48-kDa protein, corresponding to the molecular mass of the mature GFP:STLT B protein predicted from the DNA sequence (Fig. 3a) . This confirmed the capability of the pNIES-GFP to express and secrete GFP-fusion protein with fluorescent activity.
Characterization of the GFP:STLT B fusion protein secreted by the L. reuteri /pNIES-GFP:STLT B (rL. reuteri ) Quantification of the secreted GFP:STLT B fusion protein using a gel-protein scan is shown in Fig. 3 . Four hours after the inoculation, the yield of fusion protein in the supernatants of the nisin-induced rL. Reuteri 3-3 and rL. reuteri 20016 was estimated to be 14.3 and 13.6 mg L À1 (Fig. 3a) , respectively, whereas the yield in the supernatants of the noninduced cultures was 2.6 and 2.1 mg L À1 , respectively (Fig. 3b ). Because the rL. reuteri concentration used in each analysis was about 1 Â 10 8 CFU mL À1 , the amounts of GFP:STLT B (pg) secreted per cell in the aforementioned groups could thus be estimated to be 0.14, 0.13, 0.026, and 0.021, respectively. To estimate the ganglioside-binding ability of the GFP:STLT B protein, a G M1 ELISA was performed, in which significantly (P o 0.05) higher binding indexes (i.e. optical absorbance readings), compared with those in the negative controls, were detected in the culture supernatants of both rL. reuteri strains (Fig. 4) , demonstrating the capability of GFP:STLT B to bind to the gangliosides purified from intestinal epithelial cells. Moreover, as anti-LT B was used in the ELISA test, this positive result also confirmed the existence of LT B antigenicity in the GFP:STLT B protein.
To detect the possible ST toxicity remained in the fusion protein, the GFP:STLT B was orally administered to mice at doses as high as 1000 and 10 000 ng, respectively. The gastrointestinal fluid influx responses, measured as a G/C ratio, with both doses were less than the positive threshold of ST toxicity (i.e. 0.09) determined in this study (Table 2) . This, on the contrary, was found to be accomplished by only a mere 15 ng of the purified ST. Thus, as shown in Table 2 , the no observed adverse effect level (NOAEL) of GFP:STLT B (>208 pmol) was calculated to be >27 times (208/7.5) greater than that of the purified ST ( o 7.5 pmol), indicat-ing the relative freedom from the ST-associated toxicity in the GFP:STLT B protein.
Stability of pNIES-GFP:STLT B in rL. reuteri and transit times of rL. reuteri in gastrointestinal tract
To analyze the stability of pNIES-GFP:STLT B in rL. reuteri, rL. reuteri 20016 or rL. reuteri 3-3 was grown in MRS (48 000) 1000 ng w (21 pmol) 0.07 AE 0.003 GFP:STLT B 10 000 ng (208 pmol) 0.082 AE 0.005 Ã ST 10 ng (100 000 U mg À1 , Sigma) is the amount of toxin capable of producing a G/C ratio of Z0.083 in Swiss albino mice 3 days old as described in the Sigma product manual. However, by comparing the fluid influx observed in our experiment using BALB/c mice (3 days old), the G/C ratio of Z0.09 is determined to indicate a positive ST response in this study.
without erythromycin and analyzed for the percentage of colonies that still maintained the plasmid-encoded Em r marker at each 12-generation interval (c. 9.5 h). As shown in Fig. 5 , more than 90% of the colonies from both strains, after growing for 72 generations (c. 57 h), were still able to grow on the erythromycin-containing media, from which the stability index at this stage could thus be interpreted as 90%. However, at the 108th generations (c. 86 h), the stability indexes for both strains declined significantly, reaching only 73.5 AE 3.5% and 48.2 AE 1.8% for the rL. reuteri 3-3 and rL. reuteri 20016, respectively, indicating that the pNIES-GFP:STLT B had a better segregational stability in L. reuteri 3-3 (P o 0.01).
To investigate the persistence of rL. reuteri in gastrointestinal tract, mice were inoculated orally with a dose of c. 1 Â 10 9 CFU of the rL. reuteri 20016 or rL. reuteri 3-3. Large amounts of rL. reuteri began to appear in the feces 24 h after the administration (Fig. 6) . Although the numbers of fecal CFU in each time point of both groups were significantly different (P o 0.05) from each other, an identical fluctuation pattern of CFU along the time course was observed in both groups. This fluctuation pattern included two significant declines of CFU on the 2nd and 4th days (P o 0.05, as compared with the CFU on their last days, respectively) with a substantial presence of rL. reuteri (Em r , Flu 1 ) even 5 days after the administration. The fecal persistence time, in excess of 24 h, which is identical to that of the gastrointestinaladhesive lactic acid bacteria (Grangette et al., 2002) , strongly indicates the capability of rL. reuteri to colonize in the gastrointestinal tract.
To estimate whether our CFU counting had included any comparable colonies such as Em r lactic acid bacteria, which were sometimes found in the gastrointestinal tracts of pigs, chickens and human (Chin et al., 2005; Delgado et al., 2005; Mathur & Singh, 2005) but still not definitely in mice, a total of 100 randomly picked colonies from 10 plates, each representing a group of rL. reuteri at each day of the experiment, were subjected to fluorescent activity (Flu 1 ) analysis. The result confirmed that the counted CFU all originated from our administered rL. reuteri (Em r , Flu 1 ).
Induction of anti-STLT B immune responses by the intragastric route
We then examined whether the rL. reuteri system, after intragastric administration to mice, could induce a local and/or systemic immune response against STLT B . Serum IgG analysis (Fig. 7a ) revealed that both rL. reuteri 20016 and rL. reuteri 3-3 strains, after the final boost, elicited significant anti-STLT B IgG levels (end-point titers) of 1560 and 4160, respectively (P o 0.01, as compared with those in the negative control groups of the L. reuteri 3-3 and PBS). Notably, the immune response in the rL. reuteri 3-3 group was so rapid and strong that its IgG end-point titers of 1480, 2080 and 4160, detected at the three immunization stages (i.e. after priming, first boost, and second boost; Fig. 7a ), were significantly (P o 0.05) higher than their corresponding titers of 260, 720, and 1560, respectively, in the rL. reuteri 20016 group.
As to the mucosal immune response, analysis of the fecal STLT B -specific IgA titer revealed that, although evidence of immune activity in both control groups was not detectable, significant STLT B -specific IgA titers of 746 and 1024, after Fecal samples were collected each day after intragastric administration and bacterial recovery was estimated by plating on appropriate selective medium as described in the text. Data were obtained from a triplicate plating of each appropriate dilution. Ã Indicates significant decline of CFU on that day as compared with the previous day. the final boost, were literally recorded in the rL. reuteri 20016 and rL. reuteri 3-3 groups, respectively. Again, the rL. reuteri 3-3 demonstrated a rapid and significantly (P o 0.05) higher IgA titer than that of the rL. reuteri 20016, indicating its suitability for studying the immune response of mice to the oral live vaccine.
Challenge of immunized mice with ETEC
As successful induction of mucosal STLT B -specific IgA was observed, the patent mouse gut assay (Guidry et al., 1997) was then performed to explore whether the onset of immune responses in our rL. reuteri groups could provide substantial protection against ETEC challenge. In our preliminary PMG test, a dose response between the G/C ratio and CFU of ETEC, ranging from 3 Â 10 8 to 3 Â 10 9 , was observed ( Fig. S2) . Moreover, a dose of 3 Â 10 9 CFU of live ETEC was able to induce a serious gastrointestinal fluid influx, building up the gut weight and leading to a high G/C ratio of 0.185. Remarkable contrast was seen in the negative control (NaHCO 3 solution) group, which revealed a normal gastrointestinal tract with a G/C ratio of 0.085 only. The gross lesion of fluid accumulation in bowel, especially in cecum, was consistent with the previous observation by Richardson et al. (1984) (Fig. S3 ). This preliminary PMG test suggested a G/C ratio of Z0.10 to be the positive threshold for judging the toxic effect of ETEC in this study.
Successful protection against the ETEC challenge was seen in mice immunized with either rL. reuteri 3-3 or rL. reuteri 20016, because neither visual fluid response nor G/C ratios of Z0.10 (i.e. 0.090 and 0.095 respectively, Fig. 8 ) were recorded. In contrast, the negative control groups administered with PBS or L. reuteri 3-3 strain displayed massive fluid accumulations with G/C ratios of 0.189 and 0.140 significantly (P o 0.05) higher than the positive threshold of 0.10. Furthermore, a group of nonimmunized mice, gavaged with NaHCO 3 solution instead of the ETEC (shown as a control group in Fig. 8) , was found to have normal gastrointestinal tracts with a G/C ratio of only 0.089. This indicated that none of the materials used in this test, except the ETEC strain, was able to cause the fluid accumulation seen in the positive ETEC responses.
Discussion
Green fluorescent protein from Aequorea victoria, which has the advantages of being easily and stably detectable by epifluorescence microscopy without the need of adding substrate (or cofactor), has been demonstrated to be a superior reporter to the traditional enzymatic markers in tagging lactic acid bacteria (Geoffroy et al., 2000; Gory et al., 2001) . In our study, the gfp gene was used in the construction of an L. reuteri/pNIES-GFP:STLT B (rL. reuteri; Em r , Flu 1 ) system, which expressed the cloned STLT B gene as a GFP:STLT B fusion protein exhibiting fluorescent activity (Flu 1 ) and providing a 2nd selection marker for our rL. reuteri. More than 400 species of bacteria and a few eukaryotic fungi and protists naturally reside in an individual's digestive tract, and the CFU mL À1 of colon content usually reaches up to 10 14 (Lionetti et al., 2006) . The Lactobacillus reuteriselective Rogosa agar containing 10 mg mL À1 of erythromycin, used in many similar fecal studies, was found to grow some unexpected colonies with morphology comparable to our rL. reuteri during our preliminary test of our rL. reuteri in pigs. The possible microorganisms that appeared on it were suspected to be some yeast and Em r lactic acid bacteria, of which the latter have been reported to emerge frequently in the feces of pigs, chickens, and humans (Chin et al., 2005; Delgado et al., 2005; Mathur & Singh, 2005) but not definitively in mice. Under such circumstances, developing an rL. reuteri with a double selection marker would certainly provide better accuracy for the fecal CFU estimation.
In the fecal persistence analysis, a total of 100 colonies were examined for their double selection markers in two separate analyses, which demonstrated the freedom from Em r lactic acid bacteria in our experimental mice and also confirmed the accuracy of the CFU data. Noteworthy was that the GFP has demonstrated itself to be a reliable marker, expressing Flu 1 consistently in all tested colonies and being easily observed using an epifluorescence microscope. This may indicate the possibility of relying on the gfp gene solely as a selection marker in our rL. reuteri, which otherwise, with an antibiotic-resistant gene, is not allowed to be used in human and animals as a vaccine carrier.
As the GFP:STLT B product was the substance eventually presented by the rL. reuteri to the mucosal immune system, its characteristics relative to the suitability for use in animal study needs to be evaluated. First, its size (48 kDa), detected in the supernatant of the rL. reuteri culture (Fig. 3) , when probed with the specific anti-GFP or anti-LT B antibodies, corresponded to the expected molecular mass of the mature GFP:STLT B protein. This indicated the fusion protein was not only expressed and secreted successfully, but also preserved its important GFP and LT B antigenic properties. Second, the appearance of fluorescence, though in yellow in color, signified a successful expression and folding of GFP in the two totally different environments of cell supernatant and cytoplasm. This kind of color change has been described in the Qbiogene manual as a normal result of the excitationspectrum shift, caused by the interaction of two moieties in a fusion protein. Third, the receptor (gangliosides G M1 of the intestinal epithelial cell) binding ability, a property naturally possessed by the LT B and correlated with the mucosal immunogenicity and adjuvanticity of LT B when coadministered with other antigens (Guidry et al., 1997) , was significantly detectable in our GFP:STLT B protein. This finding strongly qualified the fusion product as an excellent vaccine candidate. Finally, the fusion product, being 4 27 times greater in NOAEL (Table 2) than the purified ST, indicating that it was free from ST-associated toxicity. The exact reason for the lost of toxicity in our GFP:STLT B fusion is not clear. However, Clements (Clements, 1990) fused an LT B upstream to the ST, resulting in a fusion protein (i.e. LT B -ST) free of toxicity, and suggested the toxic determinant of ST had been masked by the upstream LT B moiety. Accordingly, the N-terminal GFP in our GFP:STLT B product may have the same masking effect on its downstream ST. Studies are required to address this suggestion more stringently.
To induce a successful mucosal immune response, both the amount and duration of an antigen presented to the mucosa are crucial (Reveneau et al., 2002; Seegers, 2002) . The amounts of GFP:STLT B protein secreted by our rL. reuteri are predicted, from the in vitro estimation, to be 0.13-0.14 pg cell À1 during a 3-h period after the rL. reuteri have been induced by nisin and orally inoculated in mice. After that, only a basal (constitutive) amount of 0.021-0.026 pg cell À1 will be produced if they can manage to grow in the gastrointestinal tract. As there is no method available for detection of antigen levels, delivered by a vaccine carrier in gastrointestinal tract, development of a tissue section technique to calculating the GFP:STLT B amount from the Flu 1 intensity is underway.
Should this tissue section technique be developed, it would directly confirm the colonization capability of our rL. reuteri in the gastrointestinal tract, which, in this study, was only indirectly proved by the fecal persistence time that showed a typical pattern of the adhesive microorganisms (Grangette et al., 2002) . Generally, the fecal persistence time for a nonadhesive lactic acid bacteria was o 24 h after an oral inoculation of 1 Â 10 9 CFU (Oozeer et al., 2002) . The extra 4 fecal persistence days of our rL. reuteri strongly indicated their capability of colonizing in the gastrointestinal tract. Accordingly, the gradational and extended secretion of rL. reuteri in feces (Fig. 6 ) might be attributed to the periodical sloughing of the adhered rL. reuteri from the mucosal membrane.
As for the significant difference (P o 0.05) of fecal CFU between the mice strain (rL. reuteri 3-3) and human strain (rL. reuteri 20016) at each time point (Fig. 6 ), we suspect it was caused by the possible less adhesive capability of the rL. reuteri 20016, causing most of its inoculated CFU to be quickly excreted within the first 8-14 h, as would occur during normal ingestion in mice (Cunliffe-Beamer, 1998); the ones remaining on the mucosal membrane, though with the same pattern of behavior as that of the rL. reuteri 3-3, naturally would have lower CFU counts at each time point.
For many pathogens, the initial infection occurs at the mucosa of the lungs and intestines. It is therefore important to develop vaccines that can induce a mucosal immune response, mediated predominantly by the secretory IgA (sIgA), to neutralize the pathogens at the point where their initial infection and replication takes place. Furthermore, as many infections that have gained entrance through the mucosal surfaces will become systemic, the vaccines should also be able to elicit specific immunity in the systemic lymphoid tissues. In general, foreign antigens, delivered by the oral live vaccine carrier system, were able to elicit both specific sIgA and systemic serum IgG (Shaw et al., 2000; Grangette et al., 2002; Scheppler et al., 2002; Ho et al., 2005) . Failures to induce antibody response, especially when using lactobacilli as a carrier, were mainly attributable to the low concentration of antigen expressed (Shaw et al., 2000; Seegers, 2002) , although other factors, including bacteria strain, cellular location of antigen, immunization scheme and even mice breed, were also found to have certain impacts on it (Seegers, 2002) .
Our rL. reuteri successfully elicited both serum IgG and fecal IgA after the oral application of rL. reuteri 20016 or rL. reuteri 3-3 to mice. Notably, a rapid and substantially higher antibody response was seen in the latter group. To provide a possible reason for this observation, we inspected all in vitro analyses and were able to find two obvious differences existing between rL. reuteri 20016 and rL. reuteri 3-3: the plasmid stability of the vaccine vector pNIES-GFP:STLT B in rL. reuteri and the persistent CFU number of the rL. reuteri in the gastrointestinal tract. Apparently, these two differences eventually would lead to a higher level of the GFP:STLT B antigen being presented in the gastrointestinal tract by the rL. reuteri 3-3. This therefore confirmed the previous description that the level of the immune response is intimately associated with the level of the antigen expressed by an oral vaccine carrier (Seegers, 2002) . The suckling mouse model (SMM) had been well explored and found to be a simple, rapid, and reproducible assay for ST toxicity (Giannella, 1976) . To judge the ST toxicity in an SMM, the positive threshold of G/C ratio was determined to be Z0.083 (Giannella, 1976) and Z0.09 (Cárdenas & Clements, 1993) , in Swiss albino and CD-1 suckling mice, respectively. The BALB/c mice (3 days old) used in our study, and for the first time in an SMM, was found to have a lower G/C ratio of 0.075 (Table 2) when 10 ng of ST (according to Sigma, supposed to produce a G/C ratio of Z0.083 in Swiss albino mice) was orally inoculated, indicating that the degree of ST fluid response actually differs in different breeds of mice. On our visual and digital data, we therefore determined the positive threshold of G/C ratio in the BALB/c mice to be Z0.09.
In the patent mouse gut (PMG) assay for the detection of enterotoxin neutralization, direct challenge with live ETEC instead of the purified LT was also tried for the first time in our study. A dose response between the G/C ratio and CFU of ETEC, ranging from 3 Â 10 8 to 3 Â 10 9 , was observed. Notably, a significant fluid accumulation in bowel was visible in samples with a G/C ratio of Z0.10, which therefore was determined to be a positive threshold for responding to an ETEC challenge in our study. This threshold was proved to be a fair criterion in our later enterotoxin neutralization study, in which all the rL. reuteri-immunized mice with satisfactory protection from the ETEC challenge demonstrated a G/C ratio of o 0.10.
In summary, in the present study a live oral ETEC vaccine, using L. reuteri as a delivery vehicle to present the GFP-ST-LT B fusion as an antigen, is described for the first time. Satisfactory serum IgG and IgA titers as well as full protection of the ETEC challenge were demonstrated in mice immunized with our rL. reuteri. Fig. S3 . Typical responses of experimental and control mice given cholera toxin (CT) or ETEC.
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